InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,893.62
(
0.39%
)
US TECH 100
19,993.20
(
0.66%
)
Dow Jones
43,389.60
(
-0.13%
)
Brent Oil
73.10
(
3.39%
)
Bitcoin
91,414.03
(
1.72%
)
Post# of 253653
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

JJM760

Send PM Follow Ignore
Followers 5
Posts 993
Boards Moderated 0
Alias Born 06/15/2010

JJM760

Re: jq1234 post# 162205

Thursday, 06/06/2013 4:46:42 PM

Thursday, June 06, 2013 4:46:42 PM

Post# of 253653
Main point there being Criz naive and Chugai still has to run trials in the US.

Against LDK, it seems 113 has a clear tolerability advantage as well as just as good if not better efficacy (with what seems like very good brain mets activity).

I'd agree it is still too early to declare the winner but it seems to me that the market has clearly declared 113 the loser (In EGFR with CLVS as well).
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up